FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 呈交日期： 2025年11月7日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06826 | 說明 H 股 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 ...

Core Viewpoint - The company plans to utilize temporarily idle raised funds for cash management, ensuring safety and liquidity while aiming to enhance returns for the company and its shareholders [2][3][20]. Investment Overview - **Investment Purpose**: The objective is to improve the efficiency of raised funds, ensuring that the use of these funds does not affect project construction and safety, while increasing returns for the company and shareholders [3]. - **Investment Amount**: The company intends to use up to RMB 300 million (including principal) for cash management, with a validity period of 12 months from the board's approval [4][16]. - **Source of Funds**: The cash management funds will come from temporarily idle raised funds from the company's initial public offering in 2019 [5]. Fund Management - **Fund Usage**: The raised funds from the IPO amounted to RMB 1,588.29 million, with a net amount of RMB 1,529.27 million after deducting issuance costs. All funds have been deposited in a special account approved by the board [6][24]. - **Investment Projects**: The raised funds are allocated for international pharmaceutical R&D and working capital, with adjustments made to project timelines as necessary [7][23]. Investment Methodology - **Investment Products**: The company will invest in low-risk, liquid, and capital-protected products such as agreement deposits, notice deposits, time deposits, large certificates of deposit, and income certificates, with a maximum term of 12 months [10][16]. - **Implementation**: The board authorizes the management to make investment decisions within the approved limits and timeframe, with the finance department responsible for execution [11]. Cash Management Returns - **Return Allocation**: Earnings from cash management will be prioritized to cover any shortfalls in project investment amounts and will be managed according to regulatory requirements [12]. Recent Cash Management Situation - **Recent 12-Month Overview**: The authorization for cash management is valid for 12 months, allowing for rolling use of funds within the specified limits [13][14]. Board Approval Process - **Approval Details**: The board approved the cash management proposal on November 7, 2025, confirming that it would not affect the normal operation of the company's investment plans [15][21]. Impact on Company - **Operational Impact**: The planned cash management will not affect the normal operations or project funding of the company, and it aims to generate additional investment returns [20][29].

Core Viewpoint - The company plans to utilize temporarily idle raised funds for cash management to enhance fund efficiency and generate additional returns for the company and its shareholders [3][9][18]. Investment Overview - **Investment Purpose**: The aim is to improve the efficiency of raised fund usage while ensuring that it does not affect the construction and use of the raised fund projects [3]. - **Investment Amount**: The company intends to use up to RMB 300 million (including principal) for cash management, with a validity period of 12 months from the board's approval [4][14]. - **Source of Funds**: The funds for this cash management initiative come from the temporarily idle raised funds from the company's initial public offering in 2019 [5]. Investment Details - **Investment Products**: The company will invest in low-risk, liquid, and capital-protected financial products, including but not limited to agreement deposits, notice deposits, time deposits, large certificates of deposit, and income certificates [2][10]. - **Implementation Method**: The board authorizes the management to make investment decisions within the approved limits and timeframe, with the finance department responsible for execution [11][14]. Recent Cash Management Situation - The company has previously authorized cash management of up to RMB 400 million, with the latest authorization allowing for up to RMB 300 million [13][26]. Impact on the Company - The planned cash management will not affect the normal operation of the company's main business or the normal turnover of funds, and it aims to generate investment returns for the company and its shareholders [18][20]. Sponsor's Verification Opinion - The sponsor, UBS Securities, has confirmed that the cash management initiative has been approved by the board and complies with relevant laws and regulations, ensuring that it does not alter the intended use of raised funds [19][20].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 關連交易 收購一家非全資子公司的 餘下20%股權 茲提述本公司日期為2023年2月8日的公告及本公司日期為2023年3月9日的補充 公告，內容有關受讓方向前轉讓方收購目標公司20%股權。於2023年完成該項 收購後，本公司間接擁有目標公司80%股權。 (i) 張先生 ：張先生為目標公司的董事，因而屬本公司子公司層面的關連人士。 (ii) 深圳百納 ：張彩霞女士為目標公司的董事，因而屬本公司子公司層面的關 連人士。深圳百納為一家有限合夥企業，張彩霞女士為有限合夥人，擁有 深圳百納46.5%份額，因而深圳百納為張彩霞女士的聯繫人，因而亦為本公 司子公司層面的關連人士。 緒言 茲提述本公司日期為2023年2月8日的公 ...

智通财经APP讯，昊海生物科技(06826)发布公告，于2025年11月7日，该公司斥资146.18万港元回购5.31 万股股份，每股回购价格为27.34-27.6港元。 ...

Core Viewpoint - Haohai Biological Technology (06826) announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1: Share Buyback Details - The company will repurchase 53,100 shares at a total cost of HKD 1.4618 million [1] - The buyback price per share ranges from HKD 27.34 to HKD 27.60 [1]

格隆汇11月7日丨昊海生物科技(06826.HK)公告，11月7日耗资146.2万港元回购5.3万股。 ...

FF305 FF305 第 2 頁 共 8 頁 v 1.3.0 第 1 頁 共 8 頁 v 1.3.0 | 1). | 於 2025 年9月15日回購股份但尚未註銷 | 67,400 | % | HKD | 27.78 | | --- | --- | --- | --- | --- | --- | | | 變動日期 2025年9月15日 | | | | | | 2). | 於 2025 年9月16日回購股份但尚未註銷 | 10,000 | % | HKD | 27.68 | | | 變動日期 2025年9月16日 | | | | | | 3). | 於 2025 年9月17日回購股份但尚未註銷 | 18,400 | % | HKD | 28 | | | 變動日期 2025年9月17日 | | | | | | 4). | 於 2025 年9月18日回購股份但尚未註銷 | 23,500 | % | HKD | 27.63 | | | 變動日期 2025年9月18日 | | | | | | 5). | 於 2025 年9月24日回購股份但尚未註銷 | 51,900 | % | HKD | 27.21 | | | 變 ...

Core Viewpoint - Haohai Biological Technology (06826) announced plans to enhance the efficiency of raised funds by utilizing a portion of temporarily idle funds for cash management, aiming to increase company income and shareholder returns [1] Fund Utilization - The company plans to use no more than RMB 300 million (including the principal) of temporarily idle raised funds for cash management [1] - The usage period for these funds is effective for 12 months from the date of board approval [1] - Within the specified limit and timeframe, the funds can be used in a rolling manner [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 中國上海，2025年11月7日 於本公告日期，本公司之執行董事為侯永泰博士、吳劍英先生、陳奕奕女士及 唐敏捷先生；本公司之非執行董事為游捷女士、黃明先生及魏長征先生；及本公 司之獨立非執行董事為沈紅波先生、姜志宏先生、蘇治先生及楊玉社先生。 * 僅供識別 瑞银证券有限责任公司 关于上海昊海生物科技股份有限公司 使用暂时闲置募集资金进行现金管理的核查意见 （股份代號：6826） 海外監管公告 本公告乃由上海昊海生物科技股份有限公司（「本公司」）根據《香港聯合交易所有 限公司證券上市規則》第13.10B條的規定刊發。 茲載列本公司在上海證券交易所網站刊登之《瑞銀証券有限責任公司關於上海昊 海生物科技股份有限公司使用暫時閒置募集資金進行現金 ...